Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Graft vs Host Disease 1Ganglioneuroblastoma 1

Interventions

X-Rays 6Temozolomide 6Specimen Handling 6Nuclear Medicine Department, Hospital 6Magnetic Resonance Spectroscopy 6Biopsy 6Phantoms, Imaging 5Irinotecan 4Cyclophosphamide 4dinutuximab 3ulixertinib 2tipifarnib 2selpercatinib 2olaparib 2larotrectinib 2ivosidenib 2fludarabine phosphate 2erdafitinib 2ensartinib 2Topotecan 2trametinib 1tazemetostat 1talazoparib 1saponin QA-21V1 1palbociclib 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1fludarabine 1dabrafenib 1Vincristine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Hematopoietic Stem Cell Transplantation × 30 days × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡